Alpha 2.0
Login Register
» Articles » PMID: 35833299

Histological and Genetic Characterization and Follow-up of 130 Patients with Chronic Triple-negative Thrombocytosis

Overview
Journal Haematologica
Specialty Hematology
Date 2022 Jul 14
PMID 35833299
Authors
Sandrine Lemoine
Clelia Mornet
Isabelle Quintin-Roue
Marie-Christine Rousselet
Laurane Cottin
Aurelie Georgeais
Ludovic Dubouis
Francoise Boyer
Corentin Orvain
Clara Caillon
Maxime Renard
Valoris Le Brun
Lenaig Le Clech
Jean-Christophe Ianotto
Emmanuelle Genin
Barbara Burroni
Valerie Ugo
Damien Luque Paz
Eric Lippert
Affiliations
Soon will be listed here.
Citing Articles

Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience.

Blanco-Sanchez A, Gil-Manso R, de Nicolas R, Lopez-Munoz N, Colmenares R, Mas R Cancers (Basel). 2024; 16(18).

PMID: 39335122 PMC: 11430442. DOI: 10.3390/cancers16183149.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Verma T, Papadantonakis N, Peker Barclift D, Zhang L Cancers (Basel). 2024; 16(3).

PMID: 38339265 PMC: 10854658. DOI: 10.3390/cancers16030514.

Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?.

Ryou H, Lomas O, Theissen H, Thomas E, Rittscher J, Royston D Br J Haematol. 2023; 203(4):523-535.

PMID: 37858962 PMC: 10952168. DOI: 10.1111/bjh.19154.

Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.

Kent A, Schwartz M, McMahon C, Amaya M, Smith C, Tobin J Bone Marrow Transplant. 2023; 58(8):849-854.

PMID: 37185614 DOI: 10.1038/s41409-023-01987-5.

Genetic basis and molecular profiling in myeloproliferative neoplasms.

Luque Paz D, Kralovics R, Skoda R Blood. 2022; 141(16):1909-1921.

PMID: 36347013 PMC: 10646774. DOI: 10.1182/blood.2022017578.

References
1.
Chen C, Li F, Ma M, Zhang S, Liu Y, Yan Z . Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells. Int J Biol Macromol. 2019; 137:1030-1040. DOI: 10.1016/j.ijbiomac.2019.07.065. View
2.
Mambet C, Babosova O, Defour J, Leroy E, Necula L, Stanca O . Cooccurring V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. Blood. 2018; 132(25):2695-2699. DOI: 10.1182/blood-2018-04-843060. View
3.
Milosevic Feenstra J, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I . Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2015; 127(3):325-32. PMC: 4752213. DOI: 10.1182/blood-2015-07-661835. View
4.
Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabezon M . Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol. 2019; 94(10):E264-E267. DOI: 10.1002/ajh.25580. View
5.
Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour J, Ianotto J . Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2015; 127(3):333-42. DOI: 10.1182/blood-2015-07-661983. View